journal article·2025-01Open access

Engineering of Nanofibers Embedded with Targeted Nanoparticles Breaks Redox Levers for Glioblastoma Therapy

Yuan Ma, Mengqi Li, Xiao Fu, Dongchen Li, Chen Gao, Zhiwei Li, Yulin Zhang, Zhiliang Gao, Huimin Geng, Gang Li, Shilei Ni, Jiwei Cui

Advanced Functional Materials· Volume 35· Issue 3

Abstract

Abstract Glioblastoma multiforme (GBM), one of the most aggressive brain cancers, presents substantial therapeutic challenges, particularly concerning postsurgical recurrence and inherent drug resistance. In this study, a nanofiber‐based drug delivery system integrating platinum pro‐drugs and hemoglobin into mesoporous silica nanoparticles (HB/HSPt@MS NPs) is reported, which are surface‐modified with poly(ethylene glycol) (PEG) and targeting molecules, and subsequently embedded into nanofibers using an electrostatic spinning approach. Applied to the tumor site, these nanofibers leverage folate receptor overexpression on the tumor and the tumor's redox state to enable precise platinum release, inducing cell death through a targeted drug resistance pathway. The incorporation of hemoglobin is crucial as it disrupts the redox balance within GBM cells by facilitating the influx of iron ions, leading to lipid peroxidation through the Fenton reaction. This induces oxidative stress and overwhelms the cellular antioxidant mechanisms. This dual mechanism of action—direct cytotoxicity through sustained drug release and indirect cytotoxicity through induced oxidative stress—enhances the therapeutic efficacy of platinum drugs. The system effectively bypasses the blood‐brain barrier and reduces systemic toxicity, significantly improving delivery efficacy. Both in vitro and in vivo evaluations demonstrate substantial inhibition of tumor growth and recurrence, highlighting the potential for personalized GBM therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery Qilu Hospital of Shandong University Institute of Brain and Brain‐Inspired Science Cheeloo College of Medicine Shandong University Jinan Shandong 250012 China

Shandong Key Laboratory of Brain Health and Function Remodeling Jinan Shandong 250117 China

Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education School of Chemistry and Chemical Engineering Shandong University Jinan Shandong 250100 China

Department of Oral and Maxillofacial Surgery Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong 250021 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Jinan Science and Technology Bureau · Taishan Scholar Foundation of Shandong Province

References (53)

Show source-provided references
1. 10.1001/jama.2013.28031910.1001/jama.2013.280319 ↗
2. 10.1038/s41598-019-51108-w10.1038/s41598-019-51108-w ↗
3. 10.1002/jev2.1225510.1002/jev2.12255 ↗
4. 10.1021/acsnano.1c0812010.1021/acsnano.1c08120 ↗
5. 10.1016/j.ctrv.2019.10189610.1016/j.ctrv.2019.101896 ↗
6. 10.3390/ijms2210511110.3390/ijms22105111 ↗
7. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
8. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
9. 10.1002/advs.20230051710.1002/advs.202300517 ↗
10. 10.1016/j.bioactmat.2021.11.03010.1016/j.bioactmat.2021.11.030 ↗
11. 10.1016/j.addr.2023.11508310.1016/j.addr.2023.115083 ↗
12. 10.1038/s41582-022-00621-010.1038/s41582-022-00621-0 ↗
13. 10.1016/j.addr.2021.11395110.1016/j.addr.2021.113951 ↗
14. 10.1016/j.actbio.2020.11.03010.1016/j.actbio.2020.11.030 ↗
15. 10.3390/biomedicines903032410.3390/biomedicines9030324 ↗
16. 10.1016/j.neurol.2017.09.01110.1016/j.neurol.2017.09.011 ↗
17. 10.2176/jns-nmc.2021-039810.2176/jns-nmc.2021-0398 ↗
18. 10.1002/smll.20190224210.1002/smll.201902242 ↗
19. 10.1080/17425247.2019.159837510.1080/17425247.2019.1598375 ↗
20. 10.1002/adhm.20240032310.1002/adhm.202400323 ↗
21. 10.1002/advs.20220075610.1002/advs.202200756 ↗
22. 10.1038/s41392-024-01763-x10.1038/s41392-024-01763-x ↗
23. 10.1093/neuonc/noab09510.1093/neuonc/noab095 ↗
24. 10.1186/s13046-023-02686-110.1186/s13046-023-02686-1 ↗
25. 10.1080/15548627.2021.190546610.1080/15548627.2021.1905466 ↗
26. 10.1186/s12951-023-01963-710.1186/s12951-023-01963-7 ↗
27. 10.1016/j.actbio.2023.08.02110.1016/j.actbio.2023.08.021 ↗
28. 10.1016/S0169-5002(01)00430-510.1016/S0169-5002(01)00430-5 ↗
29. 10.1021/acsami.4c0428910.1021/acsami.4c04289 ↗
30. 10.3390/nano707018910.3390/nano7070189 ↗
31. 10.1007/s00259-022-05890-x10.1007/s00259-022-05890-x ↗
32. 10.1039/C5SC04049C10.1039/C5SC04049C ↗
33. 10.1016/j.biomaterials.2022.12144910.1016/j.biomaterials.2022.121449 ↗
34. 10.1002/adhm.20210078010.1002/adhm.202100780 ↗
35. 10.1021/acsami.0c0374810.1021/acsami.0c03748 ↗
36. 10.1021/acsabm.8b0062910.1021/acsabm.8b00629 ↗
37. 10.1016/j.ijbiomac.2015.05.05010.1016/j.ijbiomac.2015.05.050 ↗
38. Li X. · Adv. Funct. Mater. · 2020 · 30 · 45
39. 10.1080/09205063.2018.152646010.1080/09205063.2018.1526460 ↗
40. 10.1093/neuonc/noac11210.1093/neuonc/noac112 ↗
41. 10.1021/acsnano.2c1285710.1021/acsnano.2c12857 ↗
42. 10.7150/thno.5334610.7150/thno.53346 ↗
43. 10.1021/acsnano.8b0620110.1021/acsnano.8b06201 ↗
44. 10.1016/j.redox.2021.10197710.1016/j.redox.2021.101977 ↗
45. 10.1093/jnci/92.16.129510.1093/jnci/92.16.1295 ↗
46. 10.7150/thno.4007610.7150/thno.40076 ↗
47. 10.1186/s13046-020-01620-z10.1186/s13046-020-01620-z ↗
48. 10.1016/j.apsb.2020.06.01510.1016/j.apsb.2020.06.015 ↗
49. 10.1186/s12951-022-01264-510.1186/s12951-022-01264-5 ↗
50. 10.1093/neuonc/noac06410.1093/neuonc/noac064 ↗
51. 10.3389/fimmu.2022.103924110.3389/fimmu.2022.1039241 ↗
52. 10.1038/s41422-019-0164-510.1038/s41422-019-0164-5 ↗
53. 10.1016/j.ijbiomac.2020.03.17010.1016/j.ijbiomac.2020.03.170 ↗